(NASDAQ: SPRB) Spruce Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.51%.
Spruce Biosciences's earnings in 2026 is -$51,353,000.On average, 10 Wall Street analysts forecast SPRB's earnings for 2026 to be -$80,093,282, with the lowest SPRB earnings forecast at -$93,649,714, and the highest SPRB earnings forecast at -$68,773,694. On average, 10 Wall Street analysts forecast SPRB's earnings for 2027 to be -$36,969,004, with the lowest SPRB earnings forecast at -$75,708,400, and the highest SPRB earnings forecast at $36,109,962.
In 2028, SPRB is forecast to generate -$36,749,142 in earnings, with the lowest earnings forecast at -$49,232,992 and the highest earnings forecast at -$16,265,477.